Skip to content

Use of Virechana and Punaranvadi niruha basti in stage I and stage II of Chronic kidney disease.

A STUDY TO EVALUATE THE EFFECTIVENESS OF VIRECHANA KARMA AND PUNARNAVADI NIRUHA BASTI ALONG WITH SHAMANA CHIKITSA IN STAGE I AND STAGE II CHRONIC KIDNEY DISEASE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022317
Enrollment
20
Registered
2019-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N182- Chronic kidney disease, stage 2 (mild)

Interventions

Intervention1: Virechana Karma,Punarnavadi Niruha Basti,shamana chikitsa: After Snehapana and Abhayang & Baspa svedana, Virechana will be performed in the patients with the help of Katuki Churna 5-7 g

Sponsors

J S AYURVED MAHAVIDYALAYA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients fulfilling the diagnostic criteria. 2. Patients having age between 18 to 65 years of both gender will be included for the study. 3. Patients having serum creatinine level less than 3.0 mg/dl. 4. Patients indicated for Virechana and Basti.

Exclusion criteria

Exclusion criteria: 1. Female patients having pregnancy, breast feeding or post-delivery period. 2. Patients of end stage renal disease 3. Patients who are on dialysis treatment from more than 1 month period. Patients who are already operated for renal transplantation and then having nephropathy. 4. Patients of hepato-renal insufficiency or renal insufficiency due to haemodynemic circulatory disorders and CCF. 5. Patients with some serious illness like cardio-vascular diseases, psychological disorders, serious acute organic diseases, serious chronic co-morbidities, hypo or hyper thyroidism, liver or metabolic disorders etc. 6. Patients on renal replacement therapy. 7. Patients with bleeding piles or any other bleeding disorders. 8. Patients contraindicated for Virechana and Basti.

Design outcomes

Primary

MeasureTime frame
Notify improvement in signs and symptoms and laboratory investigations in the patientsTimepoint: The outcome will be assessed after 56 days of treatment in comparison to before treatment measures in the patients

Secondary

MeasureTime frame
NILTimepoint: NOT APPLICABLE

Countries

India

Contacts

Public ContactDR SUPPOSE MAURYA

J S AYURVEDA MAHAVIDYALAYA

drkalapi@rediffmail.com9428661664

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026